Summary
Grifols, S.A. (Grifols) is a pharmaceutical and chemical company focused at improving the health and well being of people around the world. It carries out the research, development, manufacturing and marketing of plasma-derived therapies, diagnostic products and hospital pharmacy products. It produces plasma derived protein therapies for patients suffering with rare, genetic diseases and life-threatening infections. Grifols has plasma donation centers across the US and industrial facilities in Australia, Mexico, Switzerland, the US and Spain. It established a system that carries out operations from collecting source plasma to the fractionation, purification and production of the finished product. Grifols is headquartered in Sant Cugat del Valles, Barcelona, Spain.
Grifols, S.A. (GRF) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Grifols, S.A., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Grifols, S.A., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
Grifols, S.A., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Grifols, S.A., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
Grifols, S.A., Medical Devices Deals, 2010 to YTD 2016 11
Grifols, S.A., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 12
Grifols, S.A., Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 14
Grifols Acquires Xepol Programme And Intellectual Property Related To PPS From Pharmalink 16
Talecris BioTherapeutics Acquires Three Plasma Centers From International BioResources 18
Partnerships 19
Grifols Enters into Agreement with MassBiologics 19
Cadence Pharma Enters Into Development Agreement With Labs Grifols For Ofirmev Injection 20
Talecris Biotherapeutics Enters Into Co-Promotion Agreement With Novartis Vaccines And Diagnostics 22
Licensing Agreements 23
Grifols Enters Into Licensing Agreement With Cumberland Pharma For Caldolor 23
Equity Offering 24
Grifols to Invest USD4 Million in AlbaJuna Therapeutics 24
TiGenix Completes Private Placement Of Shares For US$16.2 Million 25
Debt Offering 27
Grifols Completes Public Offering Of Bonds Due 2022 For US$1 Billion 27
Grifols Completes Public Offering Of 8.25% Bonds For US$1,100 Million 28
Asset Transactions 29
Kedrion Completes Acquisition Of Fractionation Facility And Plasma Collection Centers From Grifols 29
Acquisition 30
Grifols Acquires Additional 32.93% Stake in Progenika Biopharma for USD27 Million 30
Grifols to Acquire 45% Stake in Alkahest for USD37.5 Million 31
Alken Asset Management Sells 2.72% Stake In Grifols For US$227 Million 32
Grifols Completes Acquisition Of 35% Stake In Aradigm For US$26 Million 33
Grifols Acquires 60% Stake In Progenika Biopharma For US$48 Million 35
Grifols Acquires 40% Stake In VCN Biosciences, Maker Of Cancer Treatments 37
Grifols Acquires 51% Stake In Araclon Biotech 38
Grifols Completes Acquisition Of Talecris Biotherapeutics 39
Diagnostic Grifols Sells 35% Stake In Quest International, Regents and Analysis Instruments Manufacturer 42
Gri Cel Acquires 51% Stake In Nanotherapix, Cell Therapy Company, For US$2 Million 43
Grifols, S.A. - Key Competitors 44
Key Employees 45
Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51
List of Tables
Grifols, S.A., Pharmaceuticals & Healthcare, Key Facts, 2015 1
Grifols, S.A., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Grifols, S.A., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
Grifols, S.A., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Grifols, S.A., Deals By Therapy Area, 2010 to YTD 2016 9
Grifols, S.A., Medical Devices Deals, 2010 to YTD 2016 11
Grifols, S.A., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 12
Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 14
Grifols Acquires Xepol Programme And Intellectual Property Related To PPS From Pharmalink 16
Talecris BioTherapeutics Acquires Three Plasma Centers From International BioResources 18
Grifols Enters into Agreement with MassBiologics 19
Cadence Pharma Enters Into Development Agreement With Labs Grifols For Ofirmev Injection 20
Talecris Biotherapeutics Enters Into Co-Promotion Agreement With Novartis Vaccines And Diagnostics 22
Grifols Enters Into Licensing Agreement With Cumberland Pharma For Caldolor 23
Grifols to Invest USD4 Million in AlbaJuna Therapeutics 24
TiGenix Completes Private Placement Of Shares For US$16.2 Million 25
Grifols Completes Public Offering Of Bonds Due 2022 For US$1 Billion 27
Grifols Completes Public Offering Of 8.25% Bonds For US$1,100 Million 28
Kedrion Completes Acquisition Of Fractionation Facility And Plasma Collection Centers From Grifols 29
Grifols Acquires Additional 32.93% Stake in Progenika Biopharma for USD27 Million 30
Grifols to Acquire 45% Stake in Alkahest for USD37.5 Million 31
Alken Asset Management Sells 2.72% Stake In Grifols For US$227 Million 32
Grifols Completes Acquisition Of 35% Stake In Aradigm For US$26 Million 33
Grifols Acquires 60% Stake In Progenika Biopharma For US$48 Million 35
Grifols Acquires 40% Stake In VCN Biosciences, Maker Of Cancer Treatments 37
Grifols Acquires 51% Stake In Araclon Biotech 38
Grifols Completes Acquisition Of Talecris Biotherapeutics 39
Diagnostic Grifols Sells 35% Stake In Quest International, Regents and Analysis Instruments Manufacturer 42
Gri Cel Acquires 51% Stake In Nanotherapix, Cell Therapy Company, For US$2 Million 43
Grifols, S.A., Key Competitors 44
Grifols, S.A., Key Employees 45
Grifols, S.A., Other Locations 46
Grifols, S.A., Subsidiaries 47
List of Figures
Grifols, S.A., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Grifols, S.A., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Grifols, S.A., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Grifols, S.A., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Grifols, S.A., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Grifols, S.A., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 7
Grifols, S.A., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Grifols, S.A., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
Grifols, S.A., Medical Devices Deals, 2010 to YTD 2016 11
